Bank of America Issues Pessimistic Forecast for Kura Oncology (NASDAQ:KURA) Stock Price

Kura Oncology (NASDAQ:KURA) had its target price decreased by equities researchers at Bank of America from $36.00 to $29.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Bank of America‘s target price indicates a potential upside of 168.52% from the stock’s previous close.

A number of other equities analysts also recently commented on the stock. UBS Group initiated coverage on shares of Kura Oncology in a report on Thursday, October 24th. They issued a “buy” rating and a $27.00 target price for the company. Stifel Nicolaus cut shares of Kura Oncology from a “buy” rating to a “hold” rating and decreased their target price for the company from $26.00 to $19.00 in a research report on Monday, October 14th. Wedbush reaffirmed an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a report on Monday, November 4th. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Tuesday, November 19th. Finally, Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $29.38.

Kura Oncology Stock Performance

KURA stock opened at $10.80 on Friday. Kura Oncology has a twelve month low of $9.06 and a twelve month high of $24.17. The firm has a market cap of $839.81 million, a price-to-earnings ratio of -4.58 and a beta of 0.86. The business’s fifty day simple moving average is $17.88 and its two-hundred day simple moving average is $19.69. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new stake in Kura Oncology in the 1st quarter worth approximately $110,000. ProShare Advisors LLC boosted its holdings in Kura Oncology by 9.7% during the first quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock worth $384,000 after buying an additional 1,588 shares in the last quarter. Vanguard Group Inc. grew its position in Kura Oncology by 0.7% during the first quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock valued at $86,726,000 after buying an additional 28,212 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Kura Oncology by 17.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 20,148 shares of the company’s stock valued at $430,000 after buying an additional 2,940 shares in the last quarter. Finally, Artal Group S.A. raised its position in shares of Kura Oncology by 8.6% in the first quarter. Artal Group S.A. now owns 1,919,884 shares of the company’s stock worth $40,951,000 after acquiring an additional 151,828 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.